Navigation Links
Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results
Date:7/29/2010

591,587 ----------------------------------------------------------- 8,313,259 133,409,472 ----------------------------------------------------------- Loss before the following: 8,313,259 133,099,472 Interest income (20,856) (6,582,569) Gain on sale of BCY LifeSciences Inc. - (299,403) Loss on sale of Transition Therapeutics Inc. - 2,156,685 ----------------------------------------------------------- Loss before income taxes 8,292,403 128,374,185 Future income tax recovery - (1,093,000) ----------------------------------------------------------- Net loss and comprehensive loss for the period 8,292,403 127,281,185 ----------------------------------------------------------- ----------------------------------------------------------- Basic and diluted loss per share 0.18 --------------------------------------------- --------------------------------------------- Weighted average number of shares (basic and diluted) 45,659,353 --------------------------------------------- --------------------------------------------- Oncolytics Biotech Inc. CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) Three Month Three Month Six Month Period Period Period Ending June Ending June Ending June 30, 2010 30, 2009 30, 2010 $ $ $ ------------------------------------------------------------------------- OPERATING ACTIVITIES Net loss for the period
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
2. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
5. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
6. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
7. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
8. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
9. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
10. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
11. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, ... in critical areas, announced the closing of an underwritten public ... purchase up to an aggregate 3,500,000 shares of common stock, ... per warrant.  The warrants have a per share exercise price ...
(Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
(Date:12/24/2014)... GMO corn cases filed across the United ... process of being consolidated in a Kansas federal court for ... MIR 162 Corn Litigation, MDL No. 2591 in the U.S. ... the Syngenta GMO corn multidistrict litigation (MDL) has been handed ...
(Date:12/24/2014)... December 23, 2014 SoundConnect’s ... to introduce cutting edge communication technology, provide continued ... upgrades. This webinar series demonstrates online communication features ... leverage web conferencing’s most innovative and powerful tools. ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2SoundConnect Launches Leading Edge Business Communications Webinar Series 2SoundConnect Launches Leading Edge Business Communications Webinar Series 3
... 2012  Tarsa Therapeutics, Inc. today announced completion of ... by new investor Foresite Capital.  James Tananbaum, MD, ... of Directors.  Tarsa,s existing venture capital investors—Novo A/S, ... in the new financing round.  ...
... GAITHERSBURG, Md., March 15, 2012 Today GenVec, Inc. (NASDAQ: ... quarter and year ended December 31, 2011.  For the year ... of $7.4 million, or $0.58 per share, compared with a ... the year ended December 31, 2010. GenVec ended the year ...
... global carbon market requires substantial reform because it too often ... to help, according to new research from the Economic and ... released as the UN, which has designated 2012 the International ... about its Clean Development Mechanism (CDM), under which companies are ...
Cached Biology Technology:Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 2Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 3Tarsa Therapeutics Completes $28 Million Series B Financing to Advance OSTORA™ Oral Calcitonin 4GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 2GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 3GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 4GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 5GenVec Reports Fourth Quarter and 2011 Year-End Financial Results 6UN emission market needs urgent reform 2
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... http://photos.prnewswire.com/prnh/20130307/600769 ... introduced the fingerprint reading feature with the iPhone 5S. ...
(Date:12/17/2014)... BELVOIR, Va. , Dec. 15, 2014 The ... it easier to detect and prevent counterfeit microcircuits from ... agency started performing an in-house microcircuit anti-counterfeit initiative dubbed ... purchased microcircuits while increasing their reliability throughout the supply ...
(Date:12/15/2014)... Markets ( http://www.researchandmarkets.com/research/87pph8/global_facial ) has announced the ... report to their offering. ... technology used for the identification of individuals. Facial recognition ... such as nose, jaw edges, mouth, and the distance ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... Colo. Iowa State University, ConocoPhillips and the ... (NREL) have reached a Memorandum of Understanding to ... near, mid- and long-term. The collaboration will bring ... the most efficient and cost-effective methods for making ...
... 2008 - Biofuels are widely considered one of the ... and environmentalists alike. However, unless principles and standards for ... severe environmental impacts and reduce biodiversity the very ... currently the most widely used biofuel in the United ...
... neurologist on faculty in the Virginia-Maryland Regional College ... has been awarded funding from the Wake Forest ... for treating brain tumors in dogs, cats and ... in the Department of Small Animal Clinical Sciences ...
Cached Biology News:Iowa State, ConocoPhillips and National Renewable Energy Lab to cooperate on biofuels research 2Study finds concerns with biofuels 2Veterinary college researcher studying brain tumors in people and animals 2Veterinary college researcher studying brain tumors in people and animals 3
Rb anti-Occludin (C-term GST)...
anti-JNK2 Immunogen: Recombinant human JNK2 protein Accession Number: NM_002752 Quality Assurance: Routinely evaluated by immunoblot. Molecular Weight: 46 and/or 54 kDa Available ...
...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Biology Products: